Introduction {#Sec1}
============

Ovarian cancer(OC) is one of the most lethal gynecologic cancers with 22,440 new cases and 14,080 deaths anticipated by 2017 in the United States \[[@CR1]\]. Surgery is the optimal treatment for early-stage ovarian cancer, and platinum-based chemotherapy followed by debulking surgery is the standard therapy for advanced ovarian cancer. Although the development of surgery and chemotherapy improved clinical outcomes of patients with advanced ovarian cancer, the 5-year survival rate of less than 30% was still difficult to overcome. Due to the lack of specific clinical symptom and the characteristic of spreading to the abdominal cavity, most of OC have spread to peritoneum by the time of preliminary diagnosis \[[@CR2]\]. The natural feature of OC provided a perfect opportunity to develop the local therapy. A systematic review showed that intraperitoneal (IP) chemotherapy prolonged survival time and reduced the risk of death. After every cycle of IP chemotherapy finished, the risk of death decreased by 12% \[[@CR3]\]. Despite the positive clinical achievement, a higher rate of adverse events and the frequency of discontinuity hampered the adoption of IP chemotherapy \[[@CR4]\].In recent years, Intraperitoneal chemotherapy could be conveyed under hyperthermic circumstances that were termed hyperthermic intraperitoneal chemotherapy (HIPEC). Hyperthermia produced an increased number of lysosomes and lysosomal enzyme activity in malignant cells, resulting in enhanced cancer cell destruction \[[@CR5]\]. Moreover, a decreased blood flow or complete vascular stasis were observed in tumors with hyperthermia therapy, which led to accelerated cancer cell death \[[@CR6]\]. In contrast to IP chemotherapy without hyperthermia condition, HIPEC had following advantages 1) direct impairment against cancer cells 2) enhancement of the cytotoxicity of chemotherapy 3) inhibition of angiogenesis 4) improvement in denaturation of proteins 5) great tolerance without additional adverse effect \[[@CR7]--[@CR11]\] .However, due to the controversial impact of HIPEC for ovarian cancers, the role of HIPEC in the treatment of ovarian cancer is still debated. In 2015, a published meta-analysis suggested that the CRS + HIPEC +chemotherapy significantly improved 5-year overall survival rate compared to CRS + chemotherapy alone for the patients with primary ovarian cancer, but not for recurrent ovarian cancer \[[@CR12]\]. Moreover, the meta-analysis did not provide enough available data to assess the influence of HIPEC on PFS, making it difficult to estimate the clinical benefit of HIPEC comprehensively. On the basis of additional articles, we analyzed all the qualified publications by meta-analysis to evaluate the prognostic impact of HIPEC on patients with ovarian cancers with the goal of identifying the patient population who would be most likely to benefit from HIPEC.

Methods {#Sec2}
=======

Inclusion and exclusion criteria {#Sec3}
--------------------------------

In this meta-analysis, comparative clinical trials were included, and the language was restricted to English. Articles were accepted if they complied with the following inclusion criteria: (1) Patients with a diagnosis of advanced primary or recurrent ovarian cancer. (2) Interventions were performed as follows: the experimental group included ovarian cancer patients who were administered by therapy with additional hyperthermic intraperitoneal chemotherapy (HIPEC), and the patients treated with traditional treatment without HIPEC were considered as the control group. (3) The study provides available data to calculate the HR of OS or PFS. Exclusion criteria included (1) Literature reviews, Systematic reviews. (2) Case reports or Case series. (3) Animal Experiments or Cell Experiments. (4) Phase I clinical trial. (5) Duplicate publication. (6) Studies include only the HIPEC group for ovarian cancer.

Search strategy {#Sec4}
---------------

Two reviewers independently and simultaneously screened articles in the following databases: PubMed, Embase, Cochrane Library, [Clinicaltrials.gov](http://clinicaltrials.gov). MeSH terms and entry terms were used to search relevant articles.

The following is an example of the search strategy used on PubMed: (((randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR clinical trials as topic \[mesh: noexp\] OR randomly \[tiab\] OR trial \[ti\]) NOT (animals \[mh\] NOT humans \[mh\]))) AND ((((((("Hyperthermia, Induced"\[Mesh\]) OR ((((((((((((Therapy, Fever) OR Fever Therapy) OR Hyperthermia, Therapeutic)OR Therapeutic Hyperthermia) OR Thermotherapy) OR Induced Hyperthermia) OR Hyperthermic Intraperitoneal Chemotherapy) OR Chemotherapy, Hyperthermic Intraperitoneal) OR Hyperthermic Intraperitoneal Chemotherapies) OR intraperitoneal Chemotherapy, Hyperthermic) OR Hyperthermia, Local) OR Local Hyperthermia))) AND (("Ovarian Neoplasms"\[Mesh\]) OR (((((((((((((((((Neoplasm, Ovarian) OR Ovarian Neoplasm) OR Ovary Neoplasms) OR Neoplasm, Ovary) OR Ovary Neoplasm) OR Neoplasms, Ovary) OR Neoplasms, Ovarian) OR Ovary Cancer) OR Cancer, Ovary) OR Cancers, Ovary) OR Ovary Cancers) OR Ovarian Cancer) OR Cancer, Ovarian) OR Cancers, Ovarian) OR Ovarian Cancers) OR Cancer of Ovary) OR Cancer of the Ovary)))) AND surgery)). Reviews of relevant studies were searched manually to find additional eligible studies. All the Publications in these databases are up to May 15, 2018.

Quality assessment {#Sec5}
------------------

We estimated studies independently after reading the full text of each study. We used the Cochrane collaboration ROB tool to evaluate the quality of the involved randomized controlled trials (RCTs) \[[@CR13]\] (Additional file [1](#MOESM1){ref-type="media"}:Table S1). The Newcastle--Ottawa scale (NOS) was employed to assess the quality of the observational study \[[@CR14]\] (Additional file [1](#MOESM1){ref-type="media"} :Table S2 ).

Data extraction {#Sec6}
---------------

The necessary information of each trial contains the first author's name, year of publication, country, experimental design, the stage of cancer, mean age, the rate of OS, and the score of completeness of cytoreduction (CC). PFS was defined as the length of time from the start of treatment to the progression of the disease, and OS was defined as the length of time from the beginning of treatment to death. The score of CC was evaluated according to Sugarbaker \[[@CR15]\]: CC0: no residual disease; CC1: the residual disease with nodules measuring less than 2.5 mm; CC2: the residual disease with nodules measuring between 2.5 mm and 2.5 cm; and CC3: the residual nodules greater than 2.5 cm. Advanced primary ovarian cancer is defined as the stage of IC-IV in the initial diagnosis.

The hazard ratio (HR) was applied to evaluate the survival effects on PFS and OS. We extracted directly or calculated the hazard ratios and 95% confidence intervals (95% CI) from the survival curve based on the methodology of Tierney \[[@CR16]\].

Statistical analysis {#Sec7}
--------------------

We evaluate all data using Review Manager 5.3 (Cochrane Collaboration) and STATA 12.0 software (Stata Corp., College Station, TX, USA). Inter-study heterogeneity was assessed using the Chi-square test and *I* ^*2*^. A *p*-value \> 0.1 or an *I* ^*2*^ \< 50% indicate that the heterogeneity is not statistically significant, thus the fixed-effect model is used. When the opposite happens, the random-effect model was applied correspondingly. Furthermore, we make use of sensitivity analysis to analyze the stability of pooled data and exclude studies at high risk of heterogeneity. Publication bias of studies was further appraised by Egger's tests and Begg's test.

Results {#Sec8}
=======

Characteristics of included studies and quality assessment {#Sec9}
----------------------------------------------------------

According to the search strategy, we identified a total of 2383 papers. Of these,2370 references including duplication, diagnostic tests, case reports, review, and other irrelevant studies were excluded according to the exclusion criteria. A total of 13 articles were eligible for the meta-analysis. Among the included studies, there were two RCT \[[@CR17], [@CR18]\], and eleven observational studies. Our search steps are illustrated in Fig. [1](#Fig1){ref-type="fig"}.The general characteristic and scheme of thirteen articles were listed in Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"} :TableS3. The detail of quality assessment for studies is shown in supplementary of Additional file [1](#MOESM1){ref-type="media"} :TableS1 and Additional file 1: Table S2.Fig. 1Flow diagram of the literature search strategyTable 1The characteristic of studies included in meta-analysisNameArmOriginalCountryMean age(year)Patients (Numbers)StageOS (rate)I-IIIII-IVKi Sung Ryu2004Control groupPrimarySouth Korea47.760213952.8%(5-year)Experimental group46.157223563.4%(5-year)J. GORI 2005Control groupPrimaryArgentina57.01901942.1%(5-year)Experimental group55.52902955.2%(5-year)FranciscOC2009Control groupRecurrenceBulgaria541201217% (5-year)Experimental group541401457% (5-year)JIN HWI KIM 2010Control groupPrimarySouth Korea492451925%(8-year)Experimental group481971284.21%(8-year)Rene Warschkow 2012Control GroupPrimary or RecurrenceSwitzerland6590563538.3%(5-year)Experimental group58.92117472.5%(5-year)Anna Fagotti 2012Control GroupRecurrenceItaly553753237.8%(5-year)Experimental group513042676.7%(5-year)TAMAR SAFRA 2014Control GroupRecurrenceIsrael54.38477645%(5-year)Experimental group54.32722579%(5-year)Jean-Franc ¸ois Le Brun 2014Control GroupRecurrenceFranceNR1911819.4%(4-year)Experimental groupNR2322175.6%(4-year)Cascales-Campos, P. A2014Control\
GroupPrimarySpain5735035NRExperimental group5752052NRJ. Spiliotis 2015Control GroupRecurrenceGreece58.16006018%(3-year)Experimental group58.36006075%(3-year)Glauco Baiocchi 2016Control GroupRecurrenceBrazil58.450104049.5%(5-year)Experimental group51.62922749.7%(5-year)Alberto A. Mendivil 2017Control GroupPrimaryUSA62.96906975.3%(3-year)Experimental group59.86906982.6%(3-year)W.J. van Driel 2018Control GroupPrimaryNetherlands63122012238%(5-year)Experimental group61118011850%(5-year)

The association between HIPEC and OS {#Sec10}
------------------------------------

Twelve studies were eligible to assess the impact of HIPEC on OS. Pooled data demonstrated that there was an improvement in HIPEC groups compared with the groups without HIPEC treatment in all population (HR = 0.54,95% CI:0.45 to 0.66, *I*^*2*^ = 48%) (Fig.[2](#Fig2){ref-type="fig"}a). The subgroup analysis indicated that both advanced primary and recurrent patients with ovarian cancers gained significant OS benefit from HIPEC (HR = 0.59,95% CI:0.46 to 0.72, HR = 0.45,95% CI:0.24 to 0.83) (Table [2](#Tab2){ref-type="table"}).Fig. 2Forest plot assessing prognostic value and funnel plot of Begg's test between hyperthermic intraperitoneal chemotherapy group and hyperthermic intraperitoneal chemotherapy and **a** forest plot of OS **b** forest plot of PFS **c** funnel plot of OS **d** funnel plot of PFSTable 2Summary of the pooled HRStudies (*N*)HR (95%CI)*I* ^*2*^*P* valueOSPFSOS without CC3PFS without CC3OSPFSOS withoutCC3PFS withoutCC3OSPFSOS withoutCC3PFS withoutCC3HIPEC group vs non-HIPEC group130.54 (0.45-0.66)0.45(0.32-0.62)0.51(0.42-0.63)0.41(0.32-0.52)48%60%39%10%\<0.0001\<0.0001\<0.0001\<0.0001SubgroupPrimary ovarian cancer60.59(0.46-0.75)0.41(0.32-0.54)\_\_34%32%\_\_\<0.0001\<0.0001\_\_Recurrent ovarian cancer50.45(0.24 to 0.83)0.55(0.27 to 1.11)0.38(0.25 to 0.56)0.41(0.27 to 0.62)60%77%000.010.09\<0.0001\<0.0001Stage III-IV50.64(0.50 to 0.82)0.36(0.20 to 0.65)\_\_066%\--0.00040.0007\--Interval CRS plus HIPEC20.61(0.45 to 0.83)0.29(0.1 to 0.86)\--50%80%\--0.0020.03\--Primary CRS plus HIPEC100.47(0.37 to 0.61)0.52(0.41 to 0.65)0.43(0.33 to 0.55)0.43(0.33 to 0.55)50%50%28%0\<0.0001\<0.0001\<0.0001\<0.0001

The association between HIPEC and PFS {#Sec11}
-------------------------------------

Eight studies provided available data to calculate the HR of the PFS. As shown in Fig. [2](#Fig2){ref-type="fig"}b, the pooled data indicated that HIPEC improved PFS significantly compared with patients without HIPEC therapy in all population (HR = 0.45, 95% CI: 0.32 to 0.62). Among primary advanced ovarian cancers, the PFS in the HIPEC group was significantly longer (HR = 0.41, 95% CI:0.32 to 0.54). Interestingly, with regard to recurrent ovarian cancers, although the HIPEC improved the OS significantly, there was no association between HIPEC and PFS (HR = 0.55, 95% CI:0.27 to 1.11).

The influence of HIPEC in stage III or IV ovarian cancer {#Sec12}
--------------------------------------------------------

Based on the tumor stage, our pooled data also suggested that the prognostic benefit of HIPEC was also observed among patients with stage III or IV(HR = 0.64,95% CI:0.50 to 0.82, HR = 0.36,95% CI:0.20 to 0.65) (Table [2](#Tab2){ref-type="table"}).

The influence of CC3 in the meta-analysis {#Sec13}
-----------------------------------------

In the retrieval process, we found that only studies of Warschkow and Baiocchi \[[@CR19], [@CR20]\] were reported to include patients with CC3, however, Warschkow eliminated patients with CC3 when they calculated the HR. When we excluded the Baiocchi's study, the *I*^*2*^ of the pooled data decreased obviously, even the HIPEC showed useful effect on PFS of recurrent ovarian cancer, which was opposite to our pooled data (Table [2](#Tab2){ref-type="table"}). The controversy result showed that the CC3 contributed to the high heterogeneity of pooled data and displayed a critical role in the therapy value of HIPEC.

The influence of the CRS plus HIPEC timing in the meta-analysis {#Sec14}
---------------------------------------------------------------

As illustrated in Table [2](#Tab2){ref-type="table"}, both primary HIPEC plus CRS followed by chemotherapies and interval combination of HIPEC and CRS after adjuvant chemotherapies indicated improved prognostic effect on OS (HR = 0.61, 95% CI:0.45 to 0.83, HR = 0.47, 95% CI:0.37 to 0.61) and PFS (HR = 0.29, 95% CI:0.1 to 0.86, HR = 0.52, 95% CI:0.41 to 0.65).

Sensitive analysis {#Sec15}
------------------

To investigate the impact of the individual study on the pooled data, we conducted a sensitivity analysis in which every study was deleted consecutively to test the stability of the data. The result of OS and PFS was robust, sequential omission of data from any individual study did not affect the results (Fig. [3](#Fig3){ref-type="fig"}a-b).Fig. 3Sensitive analysis between HIPEC group and non-HIPEC group **a** OS **b** PFS

Publication bias {#Sec16}
----------------

As shown in Fig. [2](#Fig2){ref-type="fig"}c-d, the Begg's test and Egger's test were applied to evaluate the bias of publication, and there was no significant bias in PFS (*P*B = 0.216, *P*E = 0.147) as well as OS (*P*B = 0.086, *P*E = 0.097).

Discussion {#Sec17}
==========

To date, there is increasing evidence that the combination of CRS and HIPEC enhances the prognosis of ovarian cancer significantly \[[@CR19], [@CR21]--[@CR27]\]. However, in recent years, some studies demonstrated that the HIPEC did not show any improvement in OS compared with the therapy without the HIPEC \[[@CR20], [@CR28]\]. Thus, whether HIPEC offered benefit to patients is still under debate. Although the previous meta-analysis had revealed the association between HIPEC and better clinical prognosis, the positive effect was only applicable to the primary advanced ovarian cancer. This time, we made use of HR \[[@CR29]\] instead of OR in the previous meta-analysis to describe the prognostic effect of HIPEC. Moreover, we found that a total of eight studies have qualified data to calculate the HR of PFS which omitted in the previous meta-analysis. The current meta-analysis demonstrated that the HIPEC not only improved OS significantly but also prolonged the PFS in all population. Subgroup analysis indicated that HIPEC was associated with better clinical outcome whether primary or recurrent patients. Even stage III or IV ovarian cancer patients could benefit from HIPEC. Noticeably, deleting the study including patients with CC3 could result in the decrease of heterogeneity (Table [2](#Tab2){ref-type="table"}), which was consistent to the previous literatures that the score of CC was one of the most critical prognostic factors in advanced ovarian cancer when HIPEC followed a cytoreductive surgery \[[@CR30], [@CR31]\].

There were some limitations in the current meta-analysis. First, we searched the publications as complete as possible, only papers published in English were eligible, which may lead to selection bias. Secondly, the shortage of RCT was likely to increase the risk of bias. Thirdly, most of the studies were from observational studies, which might compromise the meta-analysis. Fourthly, factors including whether ovarian cancer resists platinum or not, pathological classification of ovarian cancer, the agency of chemotherapy medicine, and the completeness of cytoreduction were needed to be stratified further to determinate the most suitable candidates for HIPEC. Additionally, among 13 included studies, only van Driel reported the information about adverse events (AE) between HIPEC arm and non-HIPEC arm. There were no significant differences of AE between the two groups. For the HIPEC treatment group, the most common AE included Abdominal pain, Nausea, Vomiting, Fatigue, Pain. Most common AE of grade 3 or 4 were Abdominal pain, infection, ileus \[[@CR18]\]. Kim \[[@CR24]\] and Mendivil \[[@CR28]\] also reported a similar situation of toxicity and AE on HIPEC therapy. Finally, we hope that more RCT and well-designed observational studies are incorporated into the meta-analysis to ascertain and evaluated the effect and the toxicity of HIPEC in ovarian cancer.

Conclusion {#Sec18}
==========

Summary, HIPEC-based regimens might result in favorable PFS and OS for patients with advanced primary ovarian cancer. With regards to recurrent ovarian cancers, HIPEC only improved the OS but did not elicit positive value on the PFS. Additionally, it was associated with better clinical prognostic outcome among Stage III or IV ovarian cancer patients with the initial diagnosis. The CC3 might display a critical role in reducing the effect of HIPEC.

Additional file
===============

 {#Sec19}

Additional file 1:**Table S1**. Quality assessment of included RCT. **Table S2**.The Newcastle-Ottawa scale(NOS)scores of the included non-RCTs. **Table S3.** The scheme of studies included in meta-analysis. (DOCX 24 kb)
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:   Completeness of cytoreduction

CI

:   Confidence interval

CRS

:   Cytoreductive surgery
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:   The adenomatous polyposis coli
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